Mural Oncology (NASDAQ:MURA) Coverage Initiated by Analysts at Raymond James

Raymond James assumed coverage on shares of Mural Oncology (NASDAQ:MURA) in a report issued on Friday, Marketbeat reports. The firm issued a strong-buy rating and a $18.00 price target on the stock.

Separately, Rodman & Renshaw assumed coverage on Mural Oncology in a report on Friday, June 28th. They issued a buy rating and a $15.00 price objective for the company.

Mural Oncology Trading Up 5.0 %

Shares of MURA stock opened at $3.36 on Friday. Mural Oncology has a 1 year low of $2.88 and a 1 year high of $17.00. The stock has a fifty day moving average of $3.25 and a two-hundred day moving average of $3.53.

Mural Oncology (NASDAQ:MURA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($1.86) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.90) by $0.04. As a group, research analysts predict that Mural Oncology will post -7.54 earnings per share for the current year.

Insider Activity

In other news, CEO Caroline Loew sold 12,531 shares of the company’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $2.91, for a total value of $36,465.21. Following the completion of the sale, the chief executive officer now owns 240,391 shares in the company, valued at $699,537.81. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On Mural Oncology

Several hedge funds have recently modified their holdings of the stock. Harbor Capital Advisors Inc. acquired a new position in Mural Oncology during the second quarter valued at $115,000. Rhumbline Advisers acquired a new position in Mural Oncology during the second quarter valued at $34,000. BBR Partners LLC acquired a new position in Mural Oncology during the second quarter valued at $31,000. Acadian Asset Management LLC acquired a new position in Mural Oncology during the second quarter valued at $998,000. Finally, Nicollet Investment Management Inc. acquired a new position in Mural Oncology in the 2nd quarter worth about $308,000. 80.21% of the stock is owned by hedge funds and other institutional investors.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.